Retatrutide: A Triple Agonist's Promise for Cardiovascular-Kidney-Metabolic Syndrome
Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.
Background
The Cardiovascular-Kidney-Metabolic (CKM) syndrome represents a complex and interconnected cluster of conditions, including obesity, type 2 diabetes, hypertension, and chronic kidney disease, posing an escalating global health burden. Traditional single-target pharmacological interventions often prove insufficient in comprehensively addressing the multifaceted pathology of CKM syndrome and its progression. These reviews synthesize current evidence to evaluate the potential of retatrutide, a novel triple hormone receptor agonist, in managing the broad spectrum of CKM syndrome and its core component, obesity.
Study Design
Population
Reviews synthesizing current evidence on patients with Cardiovascular-Kidney-Metabolic (CKM) syndrome, including obesity, type 2 diabetes, hypertension, and chronic kidney disease.
Intervention
Retatrutide, a novel triple hormone receptor agonist.
Outcome
The potential of retatrutide in managing the broad spectrum of CKM syndrome and its core component, obesity.
TitrateLab articles covering Retatrutide
Written by TitrateLab, separately from the study summarized above.
